InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,267.84
(
-0.74%
)
US TECH 100
18,124.00
(
-0.57%
)
Dow Jones
39,065.26
(
-1.53%
)
Brent Oil
81.27
(
-0.33%
)
Bitcoin
67,785.77
(
-1.91%
)
Post# of 251914
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119682
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 174253

Friday, 02/14/2014 7:34:06 PM

Friday, February 14, 2014 7:34:06 PM

Post# of 251914
Priority-review vouchers were a provision of the 2007 FDAAA, which enabled the granting of such a voucher for successful pursuit of a drug for a rare pediatric or tropical disease. NVS received a voucher when the FDA approved Coartem for malaria in 2009 (#msg-36899805).

See #msg-33977041 and #msg-33372409 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up